Polymyalgia rheumatica and environment

What the research found.

• One trial gave 25871 adults vitamin D, omega 3, both, or neither, for a median of 5.3 years. Confirmed autoimmune disease turned up in 123 of those on vitamin D against 155 on its placebo, at a hazard ratio of 0.78 from 0.61 to 0.99. The omega 3 result was 0.85, from 0.67 to 1.08, which crosses 1.

  Hahn and colleagues, The BMJ, 2022

• One study looked at oral corticosteroid exposure across several immune diseases. Against periods off treatment, the smallest daily amount came out at a hazard ratio of 1.74 for any heart and vessel disease, from 1.64 to 1.84. In giant cell arteritis or polymyalgia rheumatica it was 1.52.

  Pujades-Rodriguez and colleagues, PLOS Medicine, 2020

• In that study, one-year risk of any heart or vessel event rose from 1.4 percent during periods off corticosteroids to 8.9 percent in the highest band. Five-year risk rose from 7.1 percent to 28.0 percent across those bands. Those are absolute figures rather than ratios, which is what makes them easier to picture.

  Pujades-Rodriguez and colleagues, PLOS Medicine, 2020

• One study looked at bone density in people with polymyalgia rheumatica, giant cell arteritis, and other vasculitis. Neither current nor total corticosteroid dose was linked to the lowest bone score. What was linked was a lower body mass index, a previous spine fracture, and use of a stomach acid drug.

  Palmowski and colleagues, Cells, 2022

• One retrospective study looked at vitamin D and remission in polymyalgia rheumatica. Baseline levels didn't differ between patients and controls, and the three-month rise in vitamin D was larger in those reaching remission. That rise predicted remission at an odds ratio of 2.89, from 1.60 to 4.11.

  Hysa and colleagues, Nutrients, 2025

An environment page with no exposures

This site holds no source measuring a chemical or workplace exposure in polymyalgia rheumatica. There's no silica figure, no solvent figure, no air pollution figure, and no smoking figure anywhere in what we hold. That's unusual on this site and worth saying at the start.

Silica appears on the lupus, systemic sclerosis, and vasculitis environment pages, and smoking leads the rheumatoid arthritis and lupus pages. Neither turns up here, in any source we hold. That absence isn't a finding, because it means no study in our source set has measured those things in this disease. This page won't guess on their behalf, and what's missing is recorded for the physician review rather than papered over.

So what follows is about the only two exposures that have been studied here. One is a supplement tested in a randomized trial. The other is the treatment that nearly everybody with this diagnosis receives, which puts a drug on an environment page and is worth a word about.

The one thing anybody randomized

One trial gave 25871 adults vitamin D, omega 3, both, or neither, and followed them for a median of 5.3 years before counting confirmed autoimmune disease. Vitamin D lowered the rate, with confirmed autoimmune disease turning up in 123 of those taking it against 155 on its placebo. That's a hazard ratio of 0.78, with the true value from 0.61 to 0.99.

Omega 3 didn't reach the usual bar, with cases at 130 against 148, at a hazard ratio of 0.85 from 0.67 to 1.08. That interval crosses 1, so the finding doesn't stand. The double-placebo group had 88 cases, and against that both supplements together gave 0.69, from 0.49 to 0.96, while vitamin D alone gave 0.68, from 0.48 to 0.94.

Now the limit that counts most, which is that the trial counted autoimmune disease of any kind. Polymyalgia rheumatica wasn't reported separately anywhere in it. So not one of those figures is about this diagnosis on its own.

Vitamin D and how this disease goes

One retrospective study asked a narrower question in this disease, which is whether vitamin D status predicted reaching early remission. Baseline vitamin D didn't differ between patients and controls at all. So this isn't a study about people starting out short of it, which is worth knowing before the rest.

What differed was the change over three months. The rise in vitamin D was a good deal larger in those who reached remission than in those with persistent disease. That rise predicted remission at an odds ratio of 2.89, from 1.60 to 4.11. Two things in that study didn't predict it at all, which are the prednisone dose and the total corticosteroid exposure somebody had taken over time.

Read the direction carefully, because this is retrospective and patients were not assigned anything. People who are getting better may absorb vitamin D differently and take supplements more reliably, and that would produce this result with the arrow pointing the other way. Nothing in the design of the study rules that out.

The exposure almost everybody here has

Nearly everybody with this diagnosis takes oral corticosteroids, often for a long time. That makes it the main exposure in this disease, and one large study set out to measure what it does. It looked across several immune diseases, comparing periods on treatment against periods off it. Risk of heart and vessel disease rose with exposure at every level, including the lowest.

Against periods off treatment, the smallest daily amount came out at a hazard ratio of 1.74 for any heart and vessel disease, from 1.64 to 1.84. That figure varied a good deal by disease, because in giant cell arteritis or polymyalgia rheumatica it was 1.52, while in lupus it was 2.82. Those are the ratios, and the absolute figures give the size better.

One-year risk of any heart or vessel event rose from 1.4 percent during periods off corticosteroids to 8.9 percent in the highest band. Five-year risk rose from 7.1 percent to 28.0 percent between those two bands. Those are the numbers most people find hardest to read calmly.

How to read that, and how not to

Those are frightening numbers to meet, especially if you've just started a treatment that works. So here's what they do and don't mean. They describe groups on different levels of the drug over years, and they don't describe you or any particular dose. No dose appears anywhere on this page, which is deliberate rather than an oversight.

They're a reason to ask about the rest of your heart risk, and a reason to ask how long treatment is planned to last. They aren't a reason to stop or reduce anything on your own. Stopping corticosteroids abruptly brings its own risks, and this disease relapses too when treatment comes off too fast. That decision belongs with the person prescribing, who can weigh both sides against what your disease is doing.

Bones, and a result that surprises people

Most people expect corticosteroid dose and bone thinning to track each other. One study of people with this disease and related ones found otherwise, and it's a result worth reading with some care. It looked at bone density in polymyalgia rheumatica, giant cell arteritis, and other kinds of vasculitis.

Current corticosteroid dose wasn't linked to the lowest bone score, and the total dose wasn't either. Three other things were linked to it, which were a lower body mass index, a previous spine fracture, and use of a stomach acid drug. All three of those were associated with lower bone density in that group.

Read that as a reason to ask, not as reassurance. It's one cross-sectional study that looked at a single moment in a group already on treatment. It doesn't show that corticosteroids are safe for bone, and nothing else on this page does either.

The context those risk figures are in

Two more findings belong here, because a corticosteroid risk figure reads very differently without them. They come before anything else you do with the numbers above. One cohort followed people in southern Norway for 38 years, and isolated polymyalgia rheumatica brought no excess risk of death.

The standard death rate ratio was 0.97, from 0.85 to 1.09. In men it was 0.77, from 0.62 to 0.95, and in women 1.11, from 0.95 to 1.28. That study is unusually complete, because by the end 96.4 percent of all patients had died, so hardly anybody was lost along the way. For giant cell arteritis the figure was 1.10, from 0.85 to 1.40.

One further study looked at cancer, and polymyalgia rheumatica wasn't associated with any increase. Cumulative incidence at ten years was 13.8 percent against 13.1 percent in a comparison group, at P equals 0.89. So the honest summary has two halves, which are that the treatment brings measurable heart and vessel risk and that people with this disease alone live as long as everybody else.

What these trials didn't test

Only one study on this page changed something and watched what happened, and that was the vitamin D trial. Everything else measured what people already had, which is a weaker kind of evidence and a different kind of claim. So the corticosteroid figures show a link rather than proof of cause.

People on more corticosteroid have more active disease, and more active disease brings plenty of other things with it besides. The vitamin D remission study is retrospective as well. So it can't say which came first either, and neither of those studies settles a cause.

What all of this supports is a conversation rather than a decision you make on your own, and that's a real use for it. Ask about your heart risk, ask about bone protection, and ask how long the treatment is planned for. Those three questions are what this evidence is genuinely good for.

Common misconceptions.

Cautions specific to this condition.

• Ask about your heart risk as well as your joints. Corticosteroid exposure was associated with heart and vessel risk at every level in one study, including the lowest.
• Don't stop or change a corticosteroid on the strength of a figure from this page. Every number here describes groups, and stopping abruptly brings its own risks.
• Ask about bone protection anyway. One study found dose unrelated to bone density and found low body weight, a previous spine fracture, and a stomach acid drug all linked to it.
• Take the vitamin D trial as evidence about autoimmune disease in general. It didn't report this disease separately.
• This page gives no vitamin D dose, no target level, and no corticosteroid dose. Those are your team's decisions.
• Tell your team about work or chemical exposures anyway. Our set holds nothing measuring them here, which isn't the same as knowing they don't count.

Questions patients ask.